Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Angiogenesis and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3864
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Angiogenesis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Angiogenesis and Peptides.

    To find out more about Triple Analysis: Leukemia, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
7TM Pharma
Abbott
Abiogen
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alexion
Alfa Wassermann
Allostera
Allosterix
Alnylam
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anchor Therapeutics
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Arana Therapeutics
Arca biopharma
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Baxter International
Bayer
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
BioSante
Bioton
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Cephalon
ChemoCentryx
Chemokine Therapeutics
Chiasma
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cornerstone Pharmaceuticals
CSL
Cue Biotech
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Digna Biotech
Dong-A
Dongkook Pharm
Dyax
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
Formula Pharmaceuticals
Galena Biopharma
GammaCan
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GlycoMimetics
GP Pharm
Green Cross
Gryphon Therapeutics
Hanmi
Hayashibara
Heber Biotec
Hoffmann-La Roche
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
Innovive
Insys Therapeutics
Intas Biopharmaceuticals
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kanisa
Karus Therapeutics
Karyon-CTT
Kinex
Kirax
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
Marillion Pharmaceuticals
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Memgen
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
NewSouth Innovations
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Novartis
Novelix
Novogen
Noxxon
NPS Pharmaceuticals
Oasmia
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
ProMetic Life Sciences
Protagonist
Protein Sciences
Protgen
PTC Therapeutics
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
Rexahn
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Serometrix
Servier
Shenogen
Shionogi
Shire
Sidus
Simcere Pharmaceuticals
Soligenix
Southern Research Institute
Spear Therapeutics
Spectrum Pharmaceuticals
Spirogen
SRI International
Stainwei Biotech
Stemline Therapeutics
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Syntrix
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Targa Therapeutics
TargeGen
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Trion Pharma
UCB
Unigene
United Biomedical
Valeant
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
XBiotech
Xencor
Xerion
Xigen
Yamasa Corporation
Zelos Therapeutics
Zensun
Zenyaku Kogyo
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AEZS-108
afamelanotide
aflibercept
alemtuzumab
AMG-386
amonafide malate
amsacrine
angiopep+paclitaxel
Angiozyme
apatinib
ARQ-197
atrasentan
axitinib
barasertib
belinostat
bevacizumab
BIBF-1120
bisantrene
BMS-690514
bosutinib
brivanib alaninate
CBP-501
cediranib
cilengitide
cladribine
clofarabine
corticorelin acetate
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
deslorelin
DI-17E6
dovitinib lactate
E-75
E-7820
elacytarabine
emepepimut-S
endostatin
ENMD-2076
enocitabine
enzastaurin hydrochloride
EP-100
everolimus
Exherin
foretinib
fosbretabulin tromethamine
FPI-01
gemtuzumab ozogamicin
GliaAtak
goserelin
GT-111
GV-1001
GX-301
HBP-347
Her-2/Neu peptides
histamine dihydrochloride
histrelin
icrucumab
idarubicin
imatinib mesilate
imMucin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
intetumumab
IPP-204106
ISA-P53-01
JI-101
kahalalide F
lanreotide
lenvatinib
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
lumiliximab
LY-2275796
MDX-1379
MGCD-265
midostaurin
mitoxantrone
motesanib diphosphate
muparfostat (IV)
NAFB001
netupitant
NGR-TNF
nilotinib
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
ON-01910
OTS-102
ozarelix
paclitaxel
PancAtak
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
pentostatin
PF-4856884
plitidepsin
polyclonal antibody stimulator
ponatinib
ProstAtak
PTC-299
RAF-265
ramucirumab
razoxane
regorafenib
rhIFN-alpha
ridaforolimus
rindopepimut
rituximab
romurtide
sirolimus
sobuzoxane
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
tamibarotene
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
teniposide
thymalfasin
tipifarnib
tivozanib
TM-30339
TRC-105
vandetanib
vapreotide, immediate-release
vismodegib
vitespen
volociximab
vosaroxin
VX-001
XL-184
XL-647
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Angiogenesis and Peptides.
    To find out more about Triple Analysis: Leukemia, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Colorectal Cancer, Lung Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Oncology Drug Pathway Analyzer - Desktop App
Get instant, interactive pathway modeling on more than 3,800 cancer drugs across more than 100 different cancer types. Learn More


Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis. Learn More